Albumin and multiple sclerosis

BMC Neurology

Volumn 16, Issue 1, 2016, Pages

  LeVine, Steven M ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Albumin; Albumin quotient; Blood brain barrier; Cerebrospinal fluid; Experimental autoimmune encephalomyelitis; Macrophages; Multiple sclerosis; Reactive nitrogen species; Reactive oxygen species

Indexed keywords

ALBUMIN; HOMOCYSTEINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; ALBUMINOID; CYTOKINE; GLUTAMIC ACID;

ANTIOXIDANT ACTIVITY; ASTROCYTE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE ACTIVITY; HUMAN; MACROPHAGE; MICROENVIRONMENT; MICROGLIA; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY;

ALBUMINS; BLOOD-BRAIN BARRIER; CYTOKINES; GLUTAMIC ACID; HUMANS; MICROGLIA; MULTIPLE SCLEROSIS; NEURONS;

EID: 84979658361     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-016-0564-9     Document Type: Review

References (196)

1. Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun. 2014;48-49:134-42.
2. Milo R, Miller A. Revised diagnostic criteria of multiple sclerosis. Autoimmun Rev. 2014;13:518-24.
3. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol. 1993;34:661-9.
4. Brück W, Bitsch A, Kolenda H, Brück Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol. 1997;42:783-93.
5. Larochelle C, Alvarez JI, Prat A. How do immune cells overcome the blood-brain barrier in multiple sclerosis? FEBS Lett. 2011;585:3770-80.
6. Vos CM, Geurts JJ, Montagne L, van Haastert ES, Bö L, van der Valk P, Barkhof F, de Vries HE. Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol Dis. 2005;20:953-60.
7. Kwon EE, Prineas JW. Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J Neuropathol Exp Neurol. 1994;53:625-36.
8. Claudio, Raine CS, Brosnan CF. Evidence of persistent blood-brain barrier abnormalities in chronic-progressive multiple sclerosis. Acta Neuropathol. 1995;90:228-38.
9. Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol. 1998;43:809-14.
10. Goodkin DE, Rooney WD, Sloan R, Bacchetti P, Gee L, Vermathen M, Waubant E, Abundo M, Majumdar S, Nelson S, Weiner MW. A serial study of new MS lesions and the white matter from which they arise. Neurology. 1998;51:1689-97.
11. Werring DJ, Brassat D, Droogan AG, Clark CA, Symms MR, Barker GJ, MacManus DG, Thompson AJ, Miller DH. The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain. 2000;123:1667-76.
12. Plumb J, McQuaid S, Mirakhur M, Kirk J. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol. 2002;12:154-69.
13. Guttmann CR, Rousset M, Roch JA, Hannoun S, Durand-Dubief F, Belaroussi B, Cavallari M, Rabilloud M, Sappey-Marinier D, Vukusic S, Cotton F. Multiple sclerosis lesion formation and early evolution revisited: A weekly high-resolution magnetic resonance imaging study. Mult Scler. In press.
14. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett. 2008;582:1783-7.
15. Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: from bench to bedside. Mol Aspects Med. 2012;33:209-90.
16. Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol. 2014;72 Suppl 1:1-5.
17. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292-302.
18. Filippi M, Capra R, Campi A, Colombo B, Prandini F, Marcianò N, Gasparotti R, Comi G. Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996;60:526-30.
19. Silver NC, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, McDonald WI, Miller DH. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain. 1997;120:1149-61.
20. Paolillo A, Piattella MC, Pantano P, Di Legge S, Caramia F, Russo P, Lenzi GL, Pozzilli C. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA. J Neurol. 2004;251:432-9.
21. Ingle GT, Sastre-Garriga J, Miller DH, Thompson AJ. Is inflammation important in early PPMS? a longitudinal MRI study. J Neurol Neurosurg Psychiatry. 2005;76:1255-8.
22. Khaleeli Z, Ciccarelli O, Mizskiel K, Altmann D, Miller DH, Thompson AJ. Lesion enhancement diminishes with time in primary progressive multiple sclerosis. Mult Scler. 2010;16:317-24.
23. Ghezzi A, Moiola L, Pozzilli C, Brescia-Morra V, Gallo P, Grimaldi LM, Filippi M, G GC. Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurol. 2015;15:174.
24. McDonald WI, Miller DH, Barnes D. The pathological evolution of multiple sclerosis. Neuropathol Appl Neurobiol. 1992;18:319-34.
25. He J, Grossman RI, Ge Y, Mannon LJ. Enhancing patterns in multiple sclerosis: evolution and persistence. AJNR Am J Neuroradiol. 2001;22:664-9.
26. Filippi M, Yousry T, Campi A, Kandziora C, Colombo B, Voltz R, Martinelli V, Spuler S, Bressi S, Scotti G, Comi G. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology. 1996;46:379-84.
27. Filippi M, Rovaris M, Capra R, Gasperini C, Yousry TA, Sormani MP, Prandini F, Horsfield MA, Martinelli V, Bastianello S, Kühne I, Pozzilli C, Comi G. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain. 1998;121:2011-20.
28. Forge JK, Pedchenko TV, LeVine SM. Iron deposits in the central nervous system of SJL mice with experimental allergic encephalomyelitis. Life Sci. 1998;63:2271-84.
29. Williams R, Rohr AM, Wang WT, Choi IY, Lee P, Berman NE, Lynch SG, LeVine SM. Iron deposition is independent of cellular inflammation in a cerebral model of multiple sclerosis. BMC Neurosci. 2011;12:59.
30. Farias AS, Martins-de-Souza D, Guimarães L, Pradella F, Moraes AS, Facchini G, Novello JC, Santos LM. Proteome analysis of spinal cord during the clinical course of monophasic experimental autoimmune encephalomyelitis. Proteomics. 2012;12:2656-62.
31. Rosenling T, Stoop MP, Attali A, van Aken H, Suidgeest E, Christin C, Stingl C, Suits F, Horvatovich P, Hintzen RQ, Tuinstra T, Bischoff R, Luider TM. Profiling and identification of cerebrospinal fluid proteins in a rat EAE model of multiple sclerosis. J Proteome Res. 2012;11:2048-60.
32. Adams CW. Perivascular iron deposition and other vascular damage in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1988;51:260-5.
33. Adams CW. A color atlas of multiple sclerosis and other myelin disorders. Dobbs Ferry, NY: Sheridan House Inc.; 1989.
34. Gay FW, Drye TJ, Dick GW, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain. 1997;120:1461-83.
35. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, Ousman SS, Fernald GH, Gerlitz B, Robinson WH, Baranzini SE, Grinnell BW, Raine CS, Sobel RA, Han DK, Steinman L. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature. 2008;451:1076-81.
36. Duzhak T, Emerson MR, Chakrabarty A, Alterman MA, LeVine SM. Analysis of protein induction in the CNS of SJL mice with experimental allergic encephalomyelitis by proteomic screening and immunohistochemistry. Cell Mol Biol (Noisy-le-Grand). 2003;49:723-32.
37. Traugott U, Raine CS, McFarlin DE. Acute experimental allergic encephalomyelitis in the mouse: immunopathology of the developing lesion. Cell Immunol. 1985;91:240-54.
38. Juhler M, Laursen H, Barry DI. The distribution of immunoglobulins and albumin in the central nervous system in acute experimental allergic encephalomyelitis. Acta Neurol Scand. 1986;73:119-24.
39. Emerson MR, Orentas DM, Lynch SG, LeVine SM. Activation of histamine H2 receptors ameliorates experimental allergic encephalomyelitis. Neuroreport. 2002;13:1407-10.
40. Sands SA, Williams R, Marshall 3rd S, LeVine SM. Perivascular iron deposits are associated with protein nitration in cerebral experimental autoimmune encephalomyelitis. Neurosci Lett. 2014;582:133-8.
41. Kerlero de Rosbo N, Bernard CC, Simmons RD, Carnegie PR. Concomitant detection of changes in myelin basic protein and permeability of blood-spinal cord barrier in acute experimental autoimmune encephalomyelitis by electroimmunoblotting. J Neuroimmunol. 1985;9:349-61.
42. Kristensson K, Wiśniewski HM. Chronic relapsing experimental allergic encephalomyelitis. Studies in vascular permeability changes. Acta Neuropathol. 1977;39:189-94.
43. Suckling AJ, Reiber H, Kirby JA, Rumsby MG. Chronic relapsing experimental allergic encephalomyelitis. Immunological and blood--cerebrospinal fluid barrier-dependent changes in the cerebrospinal fluid. J Neuroimmunol. 1983;4:35-45.
44. Kitz K, Lassmann H, Karcher D, Lowenthal A. Blood-brain barrier in chronic relapsing experimental allergic encephalomyelitis: a correlative study between cerebrospinal fluid protein concentrations and tracer leakage in the central nervous system. Acta Neuropathol. 1984;63:41-50.
45. Goldmuntz EA, Brosnan CF, Norton WT. Prazosin treatment suppresses increased vascular permeability in both acute and passively transferred experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol. 1986;137:3444-50.
46. Sobel RA, Mitchell ME. Fibronectin in multiple sclerosis lesions. Am J Pathol. 1989;135:161-8.
47. Ly L, Barnett MH, Zheng YZ, Gulati T, Prineas JW, Crossett B. Comprehensive tissue processing strategy for quantitative proteomics of formalin-fixed multiple sclerosis lesions. J Proteome Res. 2011;10:4855-68.
48. FDA. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM354675.pdf. Access 6 Apr 2016.
49. Kremer S, Lamy J, Magnus A, Oesterle H, Jeantroux J, Trunet S, Armspach JP, Dietemann JL, de Sèze J. Evaluation of an albumin-binding gadolinium contrast agent in multiple sclerosis. Neurology. 2013;81:206-10.
50. Adams CW, Poston RN, Buk SJ, Sidhu YS, Vipond H. Inflammatory vasculitis in multiple sclerosis. J Neurol Sci. 1985;69:269-83.
51. Kirk J, Plumb J, Mirakhur M, McQuaid S. Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol. 2003;201:319-27.
52. Faustmann PM, Teutrine S, Krause D, Dermietzel R. Subarachnoidal macrophages share a common epitope with resident non-cerebral macrophages and show receptor-mediated endocytosis of albumin-gold and IgG-gold complexes. J Neuroimmunol. 1991;35:79-88.
53. Adams CW, Poston RN. Macrophage histology in paraffin-embedded multiple sclerosis plaques is demonstrated by the monoclonal pan-macrophage marker HAM-56: correlation with chronicity of the lesion. Acta Neuropathol. 1990;80:208-11.
54. Lassmann H, Suchanek G, Ozawa K. Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis. Ann Neurol. 1994;36(Suppl):S42-6.
55. Brück W, Sommermeier N, Bergmann M, Zettl U, Goebel HH, Kretzschmar HA, Lassmann H. Macrophages in multiple sclerosis. Immunobiology. 1996;195:588-600.
56. D'Aguanno S, Barassi A, Lupisella S, d'eril GM, Del Boccio P, Pieragostino D, Pallotti F, Carelli V, Valentino ML, Liguori R, Avoni P, Bernardini S, Gambi D, Urbani A, Federici G. Differential cerebro spinal fluid proteome investigation of Leber hereditary optic neuropathy (LHON) and multiple sclerosis. J Neuroimmunol. 2008;193:156-60.
57. Kabat EA, Freedman DA, Murray JP, Knaub V. A study of the crystalline albumin, gamma globulin and total protein in the cerebrospinal fluid of 100 cases of multiple sclerosis and in other diseases. Am J Med Sci. 1950;219:55-64.
58. Eickhoff K, Wikström J, Poser S, Bauer H. Protein profile of cerebrospinal fluid in multiple sclerosis with special reference to the function of the blood brain barrier. J Neurol. 1977;214:207-15.
59. Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest. 1977;37:397-401.
60. Tourtellotte WW, Ma BI. Multiple sclerosis: the blood-brain-barrier and the measurement of de novo central nervous system IgG synthesis. Neurology. 1978;28:76-83.
61. Andersson M, Alvarez-Cermeño J, Bernardi G, Cogato I, Fredman P, Frederiksen J, Fredrikson S, Gallo P, Grimaldi LM, Grønning M. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry. 1994;57:897-902.
62. Uher T, Horakova D, Tyblova M, Zeman D, Krasulova E, Mrazova K, Seidl Z, Vaneckova M, Krasensky J, Weinstock-Guttman B, Ramanathan M, Havrdova E, Zivadinov R. Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48months later. Mult Scler. Epub ahead of print.
63. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, Ohman S, Racke MK, Sharief M, Sindic CJ, Sellebjerg F, Tourtellotte WW. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol. 2005;62:865-70.
64. Liebsch R, Kornhuber ME, Dietl D, Gräfin von Einsiedel H, Conrad B. Blood-CSF barrier integrity in multiple sclerosis. Acta Neurol Scand. 1996;94:404-10.
65. Hegen H, Auer M, Zeileis A, Deisenhammer F. Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: implications for increased clinical specificity. Clin Chem Lab Med. 2015. doi: 10.1515/cclm-2015-0253.
66. Cserr HF, Cooper DN, Suri PK, Patlak CS. Efflux of radiolabeled polyethylene glycols and albumin from rat brain. Am J Physiol. 1981;240:F319-28.
67. Ling C, Sandor M, Fabry Z. In situ processing and distribution of intracerebrally injected OVA in the CNS. J Neuroimmunol. 2003;141:90-8.
68. Liddelow SA, Dziȩgielewska KM, Møllgård K, Whish SC, Noor NM, Wheaton BJ, Gehwolf R, Wagner A, Traweger A, Bauer H, Bauer HC, Saunders NR. Cellular specificity of the blood-CSF barrier for albumin transfer across the choroid plexus epithelium. PLoS One. 2014;9:e106592.
69. Johanson CE, Duncan 3rd JA, Klinge PM, Brinker T, Stopa EG, Silverberg GD. Multiplicity of cerebrospinal fluid functions: New challenges in health and disease. Cerebrospinal Fluid Res. 2008;5:10.
70. Rudick RA, Zirretta DK, Herndon RM. Clearance of albumin from mouse subarachnoid space: a measure of CSF bulk flow. J Neurosci Methods. 1982;6:253-9.
71. Magnano C, Schirda C, Weinstock-Guttman B, Wack DS, Lindzen E, Hojnacki D, Bergsland N, Kennedy C, Belov P, Dwyer MG, Poloni GU, Beggs CB, Zivadinov R. Cine cerebrospinal fluid imaging in multiple sclerosis. J Magn Reson Imaging. 2012;36:825-34.
72. Reiber H. Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor Neurol Neurosci. 2003;21:79-96.
73. Ivens S, Kaufer D, Flores LP, Bechmann I, Zumsteg D, Tomkins O, Seiffert E, Heinemann U, Friedman A. TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain. 2007;130:535-47.
74. van Vliet EA, da Costa AS, Redeker S, van Schaik R, Aronica E, Gorter JA. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain. 2007;130:521-34.
75. Braganza O, Bedner P, Hüttmann K, von Staden E, Friedman A, Seifert G, Steinhäuser C. Albumin is taken up by hippocampal NG2 cells and astrocytes and decreases gap junction coupling. Epilepsia. 2012;53:1898-906.
76. van Vliet EA, Aronica E, Gorter JA. Blood-brain barrier dysfunction, seizures and epilepsy. Semin Cell Dev Biol. 2015;38:26-34.
77. Werb Z, Bainton DF, Jones PA. Degradation of connective tissue matrices by macrophages. III. Morphological and biochemical studies on extracellular, pericellular, and intracellular events in matrix proteolysis by macrophages in culture. J Exp Med. 1980;152:1537-53.
78. Kam CM, Hudig D, Powers JC. Granzymes (lymphocyte serine proteases): characterization with natural and synthetic substrates and inhibitors. Biochim Biophys Acta. 2000;1477:307-23.
79. Finehout EJ, Franck Z, Lee KH. Towards two-dimensional electrophoresis mapping of the cerebrospinal fluid proteome from a single individual. Electrophoresis. 2004;25:2564-75.
80. Vento G, Tirone C, Lulli P, Capoluongo E, Ameglio F, Lozzi S, Cota F, Mosca F, Romagnoli C, Messana I, Castagnola M, Inzitari R. Bronchoalveolar lavage fluid peptidomics suggests a possible matrix metalloproteinase-3 role in bronchopulmonary dysplasia. Intensive Care Med. 2009;35:2115-24.
81. Ljubisavljevic S, Stojanovic I, Basic J, Vojinovic S, Stojanov D, Djordjevic G, Pavlovic D. The Role of Matrix Metalloproteinase 3 and 9 in the Pathogenesis of Acute Neuroinflammation. Implications for Disease Modifying Therapy. J Mol Neurosci. 2015;56:840-7.
82. Kanesaka T, Mori M, Hattori T, Oki T, Kuwabara S. Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77:185-8.
83. Rosenberg GA, Cunningham LA, Wallace J, Alexander S, Estrada EY, Grossetete M, Razhagi A, Miller K, Gearing A. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res. 2001;893:104-12.
84. Van Hove I, Lemmens K, Van de Velde S, Verslegers M, Moons L. Matrix metalloproteinase-3 in the central nervous system: a look on the bright side. J Neurochem. 2012;123:203-16.
85. Mirshafiey A, Asghari B, Ghalamfarsa G, Jadidi-Niaragh F, Azizi G. The significance of matrix metalloproteinases in the immunopathogenesis and treatment of multiple sclerosis. Sultan Qaboos Univ Med J. 2014;14:e13-25.
86. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol. 1996;55:300-9.
87. Fisher M, Levine PH, Weiner BH, Vaudreuil CH, Natale A, Johnson MH, Hoogasian JJ. Monocyte and polymorphonuclear leukocyte toxic oxygen metabolite production in multiple sclerosis. Inflammation. 1988;12:123-31.
88. Ruuls SR, Bauer J, Sontrop K, Huitinga I, 't Hart BA. Dijkstra CD Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol. 1995;56:207-17.
89. Oleszak EL, Zaczynska E, Bhattacharjee M, Butunoi C, Legido A, Katsetos CD. Inducible nitric oxide synthase and nitrotyrosine are found in monocytes/macrophages and/or astrocytes in acute, but not in chronic, multiple sclerosis. Clin Diagn Lab Immunol. 1998;5:438-45.
90. Brundin L, Morcos E, Olsson T, Wiklund NP, Andersson M. Increased intrathecal nitric oxide formation in multiple sclerosis; cerebrospinal fluid nitrite as activity marker. Eur J Neurol. 1999;6:585-90.
91. Calabrese V, Scapagnini G, Ravagna A, Bella R, Foresti R, Bates TE, Giuffrida Stella AM, Pennisi G. Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels. J Neurosci Res. 2002;70:580-7.
92. LeVine SM, Chakrabarty A. The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis. Ann N Y Acad Sci. 2004;1012:252-66.
93. Bizzozero OA, DeJesus G, Bixler HA, Pastuszyn A. Evidence of nitrosative damage in the brain white matter of patients with multiple sclerosis. Neurochem Res. 2005;30:139-49.
94. Koch M, Mostert J, Arutjunyan A, Stepanov M, Teelken A, Heersema D, De Keyser J. Peripheral blood leukocyte NO production and oxidative stress in multiple sclerosis. Mult Scler. 2008;14:159-65.
95. Rejdak K, Petzold A, Stelmasiak Z, Giovannoni G. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult Scler. 2008;14:59-66.
96. Ortiz GG, Macías-Islas MA, Pacheco-Moisés FP, Cruz-Ramos JA, Sustersik S, Barba EA, Aguayo A. Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Dis Markers. 2009;26:35-9.
97. Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, Botond G, Esterbauer H, Binder CJ, Witztum JL, Lassmann H. Oxidative damage in multiple sclerosis lesions. Brain. 2011;134:1914-24.
98. Hametner S, Wimmer I, Haider L, Pfeifenbring S, Brück W, Lassmann H. Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol. 2013;74:848-61.
99. Wang P, Xie K, Wang C, Bi J. Oxidative stress induced by lipid peroxidation is related with inflammation of demyelination and neurodegeneration in multiple sclerosis. Eur Neurol. 2014;72:249-54.
100. Colombo G, Clerici M, Giustarini D, Rossi R, Milzani A, Dalle-Donne I. Redox albuminomics: oxidized albumin in human diseases. Antioxid Redox Signal. 2012;17:1515-27.
101. Jiao K, Mandapati S, Skipper PL, Tannenbaum SR, Wishnok JS. Site-selective nitration of tyrosine in human serum albumin by peroxynitrite. Anal Biochem. 2001;293:43-52.
102. Carballal S, Radi R, Kirk MC, Barnes S, Freeman BA, Alvarez B. Sulfenic acid formation in human serum albumin by hydrogen peroxide and peroxynitrite. Biochemistry. 2003;42:9906-14.
103. Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, Singel D, Valeri CR, Loscalzo J. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci U S A. 1992;89:7674-7.
104. Keaney Jr. JF, Simon DI, Stamler JS, Jaraki O, Scharfstein J, Vita JA, Loscalzo J. NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J Clin Invest. 1993;91:1582-9.
105. Ghasemi M, Fatemi A. Pathologic role of glial nitric oxide in adult and pediatric neuroinflammatory diseases. Neurosci Biobehav Rev. 2014;45:168-82.
106. Laussac JP, Sarkar B. Characterization of the copper(II)- and nickel(II)-transport site of human serum albumin. Studies of copper(II) and nickel(II) binding to peptide 1-24 of human serum albumin by 13C and 1H NMR spectroscopy. Biochemistry. 1984;23:2832-8.
107. Loban A, Kime R, Powers H. Iron-binding antioxidant potential of plasma albumin. Clin Sci (Lond). 1997;93:445-51.
108. Pfeiffer S, Lass A, Schmidt K, Mayer B. Protein tyrosine nitration in cytokine-activated murine macrophages. Involvement of a peroxidase/nitrite pathway rather than peroxynitrite. J Biol Chem. 2001;276:34051-8.
109. Thomas DD, Espey MG, Vitek MP, Miranda KM, Wink DA. Protein nitration is mediated by heme and free metals through Fenton-type chemistry: an alternative to the NO/O2- reaction. Proc Natl Acad Sci U S A. 2002;99:12691-6.
110. Bian K, Gao Z, Weisbrodt N, Murad F. The nature of heme/iron-induced protein tyrosine nitration. Proc Natl Acad Sci U S A. 2003;100:5712-7.
111. Wardell M, Wang Z, Ho JX, Robert J, Ruker F, Ruble J, Carter DC. The atomic structure of human methemalbumin at 1.9 A. Biochem Biophys Res Commun. 2002;291:813-9.
112. Zunszain PA, Ghuman J, Komatsu T, Tsuchida E, Curry S. Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. BMC Struct Biol. 2003;3:6.
113. Fasano M, Fanali G, Leboffe L, Ascenzi P. Heme binding to albuminoid proteins is the result of recent evolution. IUBMB Life. 2007;59:436-40.
114. Ascenzi P, Fasano M. Serum heme-albumin: an allosteric protein. IUBMB Life. 2009;61:1118-22.
115. Monzani E, Bonafè B, Fallarini A, Redaelli C, Casella L, Minchiotti L, Galliano M. Enzymatic properties of human hemalbumin. Biochim Biophys Acta. 2001;1547:302-12.
116. Ascenzi P, Fasano M. Abacavir modulates peroxynitrite-mediated oxidation of ferrous nitrosylated human serum heme-albumin. Biochem Biophys Res Commun. 2007;353:469-74.
117. Ascenzi P, di Masi A, De Sanctis G, Coletta M, Fasano M. Ibuprofen modulates allosterically NO dissociation from ferrous nitrosylated human serum heme-albumin by binding to three sites. Biochem Biophys Res Commun. 2009;387:83-6.
118. Huang Y, Shuai Y, Li H, Gao Z. Tyrosine residues play an important role in heme detoxification by serum albumin. Biochim Biophys Acta. 1840;2014:970-6.
119. Taverna M, Marie AL, Mira JP, Guidet B. Specific antioxidant properties of human serum albumin. Ann Intensive Care. 2013;3:4.
120. Bagnato F, Hametner S, Yao B, van Gelderen P, Merkle H, Cantor FK, Lassmann H, Duyn JH. Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain. 2011;134:3602-15.
121. Mehta V, Pei W, Yang G, Li S, Swamy E, Boster A, Schmalbrock P, Pitt D. Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PLoS One. 2013;8:e57573.
122. Bamm VV, Harauz G. Hemoglobin as a source of iron overload in multiple sclerosis: does multiple sclerosis share risk factors with vascular disorders? Cell Mol Life Sci. 2014;71:1789-98.
123. Spitsin SV, Scott GS, Mikheeva T, Zborek A, Kean RB, Brimer CM, Koprowski H, Hooper DC. Comparison of uric acid and ascorbic acid in protection against EAE. Free Radic Biol Med. 2002;33:1363-71.
124. Robinson SR, Dang TN, Dringen R, Bishop GM. Hemin toxicity: a preventable source of brain damage following hemorrhagic stroke. Redox Rep. 2009;14:228-35.
125. Xiong XY, Wang J, Qian ZM, Yang QW. Iron and intracerebral hemorrhage: from mechanism to translation. Transl Stroke Res. 2014;5:429-41.
126. Liu JS, Zhao ML, Brosnan CF, Lee SC. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol. 2001;158:2057-66.
127. van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD, van der Valk P, de Vries HE. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med. 2008;45:1729-37.
128. Miljković D, Momčilović M, Stanojević Z, Rašić D, Mostarica-Stojković M. It is still not for the old iron: adjuvant effects of carbonyl iron in experimental autoimmune encephalomyelitis induction. J Neurochem. 2011;118:205-14.
129. LeVine SM. Oligodendrocytes and myelin sheaths in normal, quaking and shiverer brains are enriched in iron. J Neurosci Res. 1991;29:413-9.
130. Xie Y, Liu W, Zhang X, Wang L, Xu L, Xiong Y, Yang L, Sang H, Ye R, Liu X. Human Albumin Improves Long-Term Behavioral Sequelae After Subarachnoid Hemorrhage Through Neurovascular Remodeling. Crit Care Med. 2015;43:e440-9.
131. Bagasra O, Michaels FH, Zheng YM, Bobroski LE, Spitsin SV, Fu ZF, Tawadros R, Koprowski H. Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci U S A. 1995;92:12041-5.
132. De Groot CJ, Ruuls SR, Theeuwes JW, Dijkstra CD, Van der Valk P. Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J Neuropathol Exp Neurol. 1997;56:10-20.
133. Nagra RM, Becher B, Tourtellotte WW, Antel JP, Gold D, Paladino T, Smith RA, Nelson JR, Reynolds WF. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol. 1997;78:97-107.
134. Tran EH, Hardin-Pouzet H, Verge G, Owens T. Astrocytes and microglia express inducible nitric oxide synthase in mice with experimental allergic encephalomyelitis. J Neuroimmunol. 1997;74:121-9.
135. Miller E, Wachowicz B, Majsterek I. Advances in antioxidative therapy of multiple sclerosis. Curr Med Chem. 2013;20:4720-30.
136. Raivich G, Banati R. Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease. Brain Res Brain Res Rev. 2004;46:261-81.
137. Chen JW, Breckwoldt MO, Aikawa E, Chiang G, Weissleder R. Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis. Brain. 2008;131:1123-33.
138. Gray E, Thomas TL, Betmouni S, Scolding N, Love S. Elevated myeloperoxidase activity in white matter in multiple sclerosis. Neurosci Lett. 2008;444:195-8.
139. Forghani R, Wojtkiewicz GR, Zhang Y, Seeburg D, Bautz BR, Pulli B, Milewski AR, Atkinson WL, Iwamoto Y, Zhang ER, Etzrodt M, Rodriguez E, Robbins CS, Swirski FK, Weissleder R, Chen JW. Demyelinating diseases: myeloperoxidase as an imaging biomarker and therapeutic target. Radiology. 2012;263:451-60.
140. Salavej P, Spalteholz H, Arnhold J. Modification of amino acid residues in human serum albumin by myeloperoxidase. Free Radic Biol Med. 2006;40:516-25.
141. Bruschi M, Santucci L, Candiano G, Ghiggeri GM. Albumin heterogeneity in low-abundance fluids. The case of urine and cerebro-spinal fluid. Biochim Biophys Acta. 1830;2013:5503-8.
142. D'Aguanno S, Franciotta D, Lupisella S, Barassi A, Pieragostino D, Lugaresi A, Centonze D, D'Eril GM, Bernardini S, Federici G, Urbani A. Protein profiling of Guillain-Barrè syndrome cerebrospinal fluid by two-dimensional electrophoresis and mass spectrometry. Neurosci Lett. 2010;485:49-54.
143. Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart. 2006;92:113-4.
144. Aydin O, Ellidag HY, Eren E, Kurtulus F, Yaman A, Yilmaz N. Ischemia modified albumin is an indicator of oxidative stress in multiple sclerosis. Biochem Med (Zagreb). 2014;24:383-9.
145. den Heijer T, Vermeer SE, Clarke R, Oudkerk M, Koudstaal PJ, Hofman A, Breteler MM. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain. 2003;126:170-5.
146. Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett. 2006;580:2994-3005.
147. Di Giuseppe D, Ulivelli M, Bartalini S, Battistini S, Cerase A, Passero S, Summa D, Frosali S, Priora R, Margaritis A, Di Simplicio P. Regulation of redox forms of plasma thiols by albumin in multiple sclerosis after fasting and methionine loading test. Amino Acids. 2010;38:1461-71.
148. Zoccolella S, Tortorella C, Iaffaldano P, Direnzo V, D'Onghia M, Paolicelli D, Livrea P, Trojano M. Elevated plasma homocysteine levels in patients with multiple sclerosis are associated with male gender. J Neurol. 2012;259:2105-10.
149. Ramsaransing GS, Fokkema MR, Teelken A, Arutjunyan AV, Koch M, De Keyser J. Plasma homocysteine levels in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77:189-92.
150. Sengupta S, Chen H, Togawa T, DiBello PM, Majors AK, Büdy B, Ketterer ME, Jacobsen DW. Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine. J Biol Chem. 2001;276:30111-7.
151. Summa D, Spiga O, Bernini A, Venditti V, Priora R, Frosali S, Margaritis A, Di Giuseppe D, Niccolai N, Di Simplicio P. Protein-thiol substitution or protein dethiolation by thiol/disulfide exchange reactions: the albumin model. Proteins. 2007;69:369-78.
152. Ahn SM, Byun K, Cho K, Kim JY, Yoo JS, Kim D, Paek SH, Kim SU, Simpson RJ, Lee B. Human microglial cells synthesize albumin in brain. PLoS One. 2008;3:e2829.
153. Prajapati KD, Sharma SS, Roy N. Upregulation of albumin expression in focal ischemic rat brain. Brain Res. 2010;1327:118-24.
154. Prajapati KD, Sharma SS, Roy N. Hepatocyte nuclear factor-1alpha mediated upregulation of albumin expression in focal ischemic rat brain. Neurol Res. 2012;34:25-31.
155. Byun K, Bayarsaikhan E, Kim D, Kim CY, Mook-Jung I, Paek SH, Kim SU, Yamamoto T, Won MH, Song BJ, Park YM. Lee Induction of neuronal death by microglial AGE-albumin: implications for Alzheimer's disease. PLoS One. 2012;7:e37917.
156. Byun K, Bayarsaikhan D, Bayarsaikhan E, Son M, Oh S, Lee J, Son HI, Won MH, Kim SU, Song BJ, Lee B. Microglial AGE-albumin is critical in promoting alcohol-induced neurodegeneration in rats and humans. PLoS One. 2014;9:e104699.
157. Sternberg Z, Ostrow P, Vaughan M, Chichelli T, Munschauer F. AGE-RAGE in multiple sclerosis brain. Immunol Invest. 2011;40:197-205.
158. Sternberg Z, Hennies C, Sternberg D, Bistulfi GL, Kazim L, Benedict RH, Chadha K, Leung C, Weinstock-Guttman B, Munschauer F. Plasma pentosidine: a potential biomarker in the management of multiple sclerosis. Mult Scler. 2011;17:157-63.
159. Sakata N, Moh A, Takebayashi S. Contribution of superoxide to reduced antioxidant activity of glycoxidative serum albumin. Heart Vessels. 2002;17:22-9.
160. Van Campenhout A, Van Campenhout C, Lagrou AR, Moorkens G, De Block C, Manuel-y-Keenoy B. Iron-binding antioxidant capacity is impaired in diabetes mellitus. Free Radic Biol Med. 2006;40:1749-55.
161. Faure P, Wiernsperger N, Polge C, Favier A, Halimi S. Impairment of the antioxidant properties of serum albumin in patients with diabetes: protective effects of metformin. Clin Sci (Lond). 2008;114:251-6.
162. Liu W, Xu GZ, Jiang CH, Tian J. Macrophage colony-stimulating factor and its receptor signaling augment glycated albumin-induced retinal microglial inflammation in vitro. BMC Cell Biol. 2011;12:5.
163. Reder AT, Genç K, Byskosh PV, Porrini AM. Monocyte activation in multiple sclerosis. Mult Scler. 1998;4:162-8.
164. Claudio L, Martiney JA, Brosnan CF. Ultrastructural studies of the blood-retina barrier after exposure to interleukin-1 beta or tumor necrosis factor-alpha. Lab Invest. 1994;70:850-61.
165. Prajapati KD, Sharma SS, Roy N. Current perspectives on potential role of albumin in neuroprotection. Rev Neurosci. 2011;22:355-63.
166. Piazza O, Scarpati G. Endogenous agents that contribute to generate or prevent ischemic damage. In: Maurizio B, editor. Advances in the Preclinical Study of Ischemic Stroke. Dr. Maurizio Balestrino (Ed.), ISBN: 978-953-51-0290-8, InTech, Available from: http://www.intechopen.com/books/advances-in-the-preclinicalstudy-of-ischemic-stroke/endogenous-neuroprotective-compounds-in-stroke ; 2012. Access 6 Apr 2016.
167. Bento-Abreu A, Velasco A, Polo-Hernández E, Pérez-Reyes PL, Tabernero A, Medina JM. Megalin is a receptor for albumin in astrocytes and is required for the synthesis of the neurotrophic factor oleic acid. Neurochem. 2008;106:1149-59.
168. Tabernero A, Lavado EM, Granda B, Velasco A, Medina JM. Neuronal differentiation is triggered by oleic acid synthesized and released by astrocytes. J Neurochem. 2001;79:606-16.
169. Tabernero A, Velasco A, Granda B, Lavado EM, Medina JM. Transcytosis of albumin in astrocytes activates the sterol regulatory element-binding protein-1, which promotes the synthesis of the neurotrophic factor oleic acid. J Biol Chem. 2002;277:4240-6.
170. Hamilton JA, Era S, Bhamidipati SP, Reed RG. Locations of the three primary binding sites for long-chain fatty acids on bovine serum albumin. Proc Natl Acad Sci U S A. 1991;88:2051-4.
171. Cain LD, Nie L, Hughes MG, Johnson K, Echetebu C, Xu GY, Hulsebosch CE, McAdoo DJ. Serum albumin improves recovery from spinal cord injury. J Neurosci Res. 2007;85:1558-67.
172. Avila-Martin G, Galan-Arriero I, Gómez-Soriano J, Taylor J. Treatment of rat spinal cord injury with the neurotrophic factor albumin-oleic acid: translational application for paralysis, spasticity and pain. PLoS One. 2011;6:e26107.
173. Chang TS, Jensen MB. Haemodilution for acute ischaemic stroke. Cochrane Database Syst Rev. 2014;8:CD000103.
174. Ginsberg MD, Palesch YY, Martin RH, Hill MD, Moy CS, Waldman BD, Yeatts SD, Tamariz D, Ryckborst K. The albumin in acute stroke (ALIAS) multicenter clinical trial: safety analysis of part 1 and rationale and design of part 2. Stroke. 2011;42:119-27.
175. Christiansen CF. Risk of vascular disease in patients with multiple sclerosis: a review. Neurol Res. 2012;34:746-53.
176. Hassel B, Iversen EG, Fonnum F. Neurotoxicity of albumin in vivo. Neurosci Lett. 1994;167:29-32.
177. Kadota E, Nonaka K, Karasuno M, Nishi K, Teramura K, Hashimoto S. Neurotoxicity of serum components, comparison between CA1 and striatum. Acta Neurochir Suppl. 1997;70:141-3.
178. Chen ZL, Indyk JA, Bugge TH, Kombrinck KW, Degen JL, Strickland S. Neuronal death and blood-brain barrier breakdown after excitotoxic injury are independent processes. J Neurosci. 1999;19:9813-20.
179. Frigerio F, Frasca A, Weissberg I, Parrella S, Friedman A, Vezzani A, Noé FM. Long-lasting pro-ictogenic effects induced in vivo by rat brain exposure to serum albumin in the absence of concomitant pathology. Epilepsia. 2012;53:1887-97.
180. Ralay Ranaivo H, Wainwright MS. Albumin activates astrocytes and microglia through mitogen-activated protein kinase pathways. Brain Res. 2010;1313:222-31.
181. Rossi S, Furlan R, De Chiara V, Motta C, Studer V, Mori F, Musella A, Bergami A, Muzio L, Bernardi G, Battistini L, Martino G, Centonze D. Interleukin-1β causes synaptic hyperexcitability in multiple sclerosis. Ann Neurol. 2012;71:76-83.
182. Blauth K, Zhang X, Chopra M, Rogan S, Markovic-Plese S. The role of fractalkine (CX3CL1) in regulation of CD4(+) cell migration to the central nervous system in patients with relapsing-remitting multiple sclerosis. Clin Immunol. 2015;157:121-32.
183. Hooper C, Taylor DL, Pocock JM. Pure albumin is a potent trigger of calcium signalling and proliferation in microglia but not macrophages or astrocytes. J Neurochem. 2005;92:1363-76.
184. Marrie RA, Reider N, Cohen J, Trojano M, Sorensen PS, Cutter G, Reingold S, Stuve O. A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. Mult Scler. 2015;21:342-9.
185. Tomkins O, Friedman O, Ivens S, Reiffurth C, Major S, Dreier JP, Heinemann U, Friedman A. Blood-brain barrier disruption results in delayed functional and structural alterations in the rat neocortex. Neurobiol Dis. 2007;25:367-77.
186. Vega-Zelaya L, Ortega GJ, Sola RG, Pastor J. Plasma albumin induces cytosolic calcium oscilations and DNA synthesis in human cultured astrocytes. Biomed Res Int. 2014;2014:539140.
187. David Y, Cacheaux LP, Ivens S, Lapilover E, Heinemann U, Kaufer D, Friedman A. Astrocytic dysfunction in epileptogenesis: consequence of altered potassium and glutamate homeostasis? J Neurosci. 2009;29:10588-99.
188. Tabernero A, Granda B, Medina A, Sánchez-Abarca LI, Lavado E, Medina JM. Albumin promotes neuronal survival by increasing the synthesis and release of glutamate. J Neurochem. 2002;81:881-91.
189. Stojanovic IR, Kostic M, Ljubisavljevic S. The role of glutamate and its receptors in multiple sclerosis. J Neural Transm (Vienna). 2014;121:945-55.
190. Higashi K, Fujita A, Inanobe A, Tanemoto M, Doi K, Kubo T, Kurachi Y. An inwardly rectifying K(+) channel, Kir4.1, expressed in astrocytes surrounds synapses and blood vessels in brain. Am J Physiol Cell Physiol. 2001;281:C922-31.
191. Schirmer L, Srivastava R, Kalluri SR, Böttinger S, Herwerth M, Carassiti D, Srivastava B, Gempt J, Schlegel J, Kuhlmann T, Korn T, Reynolds R, Hemmer B. Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions. Ann Neurol. 2014;75:810-28.
192. Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, Rothhammer V, Chan A, Gold R, Berthele A, Bennett JL, Korn T, Hemmer B. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med. 2012;367:115-23.
193. Brill L, Goldberg L, Karni A, Petrou P, Abramsky O, Ovadia H, Ben-Hur T, Karussis D, Vaknin-Dembinsky A. Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse? Mult Scler. 2015;21:572-9.
194. Schneider R. Autoantibodies to Potassium Channel KIR4.1 in Multiple Sclerosis. Front Neurol. 2013;4:125.
195. Brickshawana A, Hinson SR, Romero MF, Lucchinetti CF, Guo Y, Buttmann M, McKeon A, Pittock SJ, Chang MH, Chen AP, Kryzer TJ, Fryer JP, Jenkins SM, Cabre P, Lennon VA. Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol. 2014;13:795-806.
196. Wunsch M, Rovituso DM, Kuerten S. KIR4.1 Antibodies as Biomarkers in Multiple Sclerosis. Front Neurol. 2014;5:62.